Get the Stockscreener App
4.46
15.85%
-0.84
After Hours:
4.46
Orgenesis Inc stock is traded at $4.46, with a volume of 52,276.
It is down -15.85% in the last 24 hours and down -33.42% over the past month.
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.
See More
Previous Close:
$5.30
Open:
$5.2
24h Volume:
52,276
Relative Volume:
2.48
Market Cap:
$20.93M
Revenue:
$27.75M
Net Income/Loss:
$-25.07M
P/E Ratio:
-8.5769
EPS:
-0.52
Net Cash Flow:
$-32.64M
1W Performance:
+14.36%
1M Performance:
-33.42%
6M Performance:
-45.74%
1Y Performance:
-28.06%
1-Day Range:
$4.2112
$5.20
1-Week Range:
$3.7131
$5.44
52-Week Range:
$2.50
$10.80
Orgenesis Inc Stock (ORGS) Company Profile
Name
Orgenesis Inc
Sector
Industry
Phone
(480) 659-6404
Address
20271 GOLDENROD LANE, GERMANTOWN, MD
Orgenesis Inc Stock (ORGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-18 | Initiated | Dawson James | Buy |
Orgenesis Inc Stock (ORGS) Latest News
Host of US equity, index derivatives live in two days – FOW Data - News & Insights
Orgenesis stock hits 52-week high at $3.84 amid market fluctuations - Investing.com
Orgenesis Inc (ORGS) Stock: A Year of Stock Market Dynamics - The InvestChronicle
In the Green: Orgenesis Inc (ORGS) Closes at 0.39, Up/Down -24.62 from Previous Day - The Dwinnex
Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga
Orgenesis Announces Reverse Stock Split - citybiz
Orgenesis announces reverse stock split to meet Nasdaq requirements - Investing.com
Orgenesis announces 1-for-10 reverse stock split to regain Nasdaq compliance - MSN
Orgenesis Announces Reverse Stock Split to Maintain Nasdaq Compliance - TipRanks
Orgenesis announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com UK
Orgenesis Announces Reverse Stock Split - StockTitan
ORNL shreds 250 petabytes of disk drives from the Summit supercomputer — Alpine storage system dismantled in preparation for the world's fastest supercomputer - Tom's Hardware
Monitoring Orchid Island Capital Inc (ORC) after recent insider movements - Knox Daily
Ovis gets $56m acquisition loan for 'premium' Langford rentals - Green Street News
Critical Survey: Oportun Financial (NASDAQ:OPRT) versus Gryphon Digital Mining (NASDAQ:GRYP) - Defense World
RSM advises OftalTech Solutions on the sale and purchase by Moria - Iberian Lawyer
Goroke show returns - The Weekly Advertiser
Oragenics Inc’s Market Journey: Closing Weak at 0.50, Down -6.08 - The Dwinnex
Headlands Technologies LLC Acquires New Holdings in Organon & Co. (NYSE:OGN) - Defense World
ORMOLUS: Revolutionizing the Utility Crypto Space with a Unique Dividend Ecosystem - BSC News
Ocean Power Technologies Stock Climbs On Q1 Results: Details - Benzinga
Organon & Co. (NYSE:OGN) Shares Bought by Acadian Asset Management LLC - Defense World
Oura embraces CGM technology with Veri acquisition - Gadgets & Wearables
Oura’s metabolic health plans step up with Veri buyout – here’s why it makes sense - Wareable
Latham Advises the Royal Bank of Canada and RBC Capital Markets in Connection With Methanex’s US$2.05 Billion Acquisition of OCI’s International Methanol Business - Legal Desire News Network
Artificial Insemination Market May See Big Move: Vitrolife, Orgenesis, CryoLife - openPR
Cell therapy weekly: US FDA grants Orphan Drug Designation to a gene therapy for a type of retinal disease - RegMedNet
Orgenesis Inc (ORGS) is looking forward to a strong quarter - SETE News
Upward Trajectory: Orgenesis Inc (ORGS) Posts a Slidee, Closing at 0.67 - The Dwinnex
Orgenesis’ CAR-T ORG-101 Demonstrates Efficacy and Safety in Acute Lymphoblastic Leukemia in Real-World Study in China - CGTLive™
Orgenesis reports promising CAR-T therapy results - Investing.com India
Orgenesis Releases Investor Presentation and Regulatory Update - TipRanks
Orgenesis reports promising CAR-T therapy results - Investing.com
Orgenesis reports promising CAR-T therapy results By Investing.com - Investing.com UK
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia - StockTitan
Orgenesis Inc. secures additional $750K funding - Investing.com India
Orgenesis Inc. secures additional $750K funding By Investing.com - Investing.com Canada
Orgenesis Inc. secures additional $750K funding By Investing.com - Investing.com UK
Pfizer Does Not Own Orgenesis: So Why Does This Misinformation Trend on X? - PANDA
Orgenesis Inc (ORGS) can make a big difference with a little luck - SETE News
Orgenesis stock hits 52-week high at $1.04 amid market fluctuations - Investing.com
Orgenesis forms joint venture with Harley Street Healthcare Group - Investing.com
Orgenesis forms joint venture with Harley Street Healthcare Group - Investing.com India
Orgenesis forms joint venture with Harley Street Healthcare - Investing.com
Orgenesis forms joint venture with Harley Street Healthcare - Investing.com India
Orgenesis Inc Inc. (ORGS) Price Performance: The Impact of Insider Trading and Institutional Holdings - The InvestChronicle
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally - StockTitan
Orgenesis forms joint venture with Harley Street Healthcare By Investing.com - Investing.com UK
Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Orgenesis Provides Second Quarter 2024 Business Update - ForexTV.com
Orgenesis Provides Second Quarter 2024 Business Update - StockTitan
Orgenesis Inc Stock (ORGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):